November

The FDA’s Risk Evaluation and Mitigation Strategy (REMS) for mifepristone allows patients to obtain the drug without an in-person visit to a clinician. Ongoing federal litigation has challenged the FDA’s REMS for mifepristone, seeking to add or remove restrictions. In the meantime, mifepristone access is being undermined by additional restrictions at the state level, imposed by state law. Doctors and lawyers are now working together to challenge these state restrictions and ensure that the FDA, not state legislatures, makes the rules for access to mifepristone. This session will explore the role of the law of federal preemption, its impact on practicing medicine, and how clinicians can get involved.

 

 

Use code ENGAGE to get 20% off your first year of any membership tier. The next four years demand our unwavering commitment, and Doctors for America will be ready from day one—standing alongside our advocates every step of the way. You can count on us to keep fighting for equitable, affordable, and high-quality healthcare in every arena: from clinics and hospitals to Congress, courts, local governments, and federal agencies. Guided by our core values—putting patients above profits, profession, and politics—we remain steadfast in our mission. But we can’t do it without you. Let’s unite for our patients and advance the cause of healthcare justice—together!